Efficacy of P2Y(12) receptor antagonists in patients with atrial fibrillation according to the CHA(2)DS(2)VASc score

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F16%3A00011319" target="_blank" >RIV/75010330:_____/16:00011319 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/16:43910960
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0167527316300468" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0167527316300468</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.01.039" target="_blank" >10.1016/j.ijcard.2016.01.039</a>

Result language
angličtina
Original language name
Efficacy of P2Y(12) receptor antagonists in patients with atrial fibrillation according to the CHA(2)DS(2)VASc score
Original language description
The aim of presented study was to verify whether the presence of AF impacts the efficacy of P2Y12 receptor antagonists in the group of patients after stent-PCI, and to investigate whether there is a correlation between CHA2DS2VASc score and the efficacy of P2Y12 receptor antagonists in this group of patients. The main finding of the presented study is that the presence of AF does not impact the efficacy of prasugrel or ticagrelor. For the replacement of clopidogrel one of prasugrel or ticagrelor should be considered in patients with AF who undergo stent-PCI in a setting of ACS and who are in a high risk of thrombotic events and low bleeding risk. Periprocedural administration of GP IIb/IIIa inhibitors in this high risk population increases the efficacy of clopidogrel.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)